Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

COMy 2019 | Beyond KarMMa-2: agents targeting BCMA in MM

Andrew Yee • 17 May 2019
COMy 2019
Multiple Myeloma CAR-T
KarMMa-2

Andrew Yee, MD, of Massachusetts General Hospital Cancer Center, Boston, MA, discusses the KarMMa-2 trial (NCT03601078) and further trials that also targeting BCMA. This interview took place at the Controversies in Multiple Myeloma (COMy) 2019 World Congress in Paris, France.

More from Andrew Yee

2:40
Huge potential for CAR-T therapy in myeloma
Andrew Yee • 17 May 2019

Related Videos

0:59
Looking forward to COMy 2024: celebrating 10 years
Mohamad Mohty • 17 Apr 2024
0:57
Overcoming barriers to treating older patients with myeloma
Sergio Giralt • 16 Apr 2024
1:01
The potentially curative role of CAR-T therapy in myeloma
Sergio Giralt • 16 Apr 2024
1:45
Expanded approval of cilta-cel in myeloma: the value of bringing CAR-T cells into earlier lines
Monika Engelhardt • 16 Apr 2024
The content of VJHemOnc is intended for healthcare professionals